News - Affymax


Current filters:


Popular Filters

Takeda to withdraw NDA as Omontys pact with Affymax ends

Takeda to withdraw NDA as Omontys pact with Affymax ends


USA-based Affymax and Japan's Takeda Pharmaceutical revealed on Friday that they have terminated their…

AffymaxBiotechnologyLicensingOmontysOncologyRegulationTakeda Pharmaceutical

Affymax slashes workforce following Omontys problems; evaluating options


US biopharma company Affymax (Nasdaq: AFFY) says that it will reduce its workforce as part of a plan…


Takeda and Affymax recall all lots of anemia drug Omontys


US drugmaker Affymax (Nasdaq: AFFY) and its licensee, Japan's Takeda Pharmaceutical (TYO: 4502), said…

AffymaxMarkets & MarketingNorth AmericaOmontysPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda and Affymax in supply deal for Omontys injection with US Renal Care


Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) and Affymax (Nasdaq: AFFY) have said that…

AffymaxMarkets & MarketingNephrology and HepatologyNorth AmericaOmontysPharmaceuticalTakeda Pharmaceuticals

FDA backs Affymax and Takeda drug Omontys for anemia due to CKD


The US Food and Drug Administration yesterday approved Omontys (peginesatide, formerly known as Hematide)…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontyspeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Takeda to drop peginesatide commercialization in Japan


Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has decided not to commercialize peginesatide…

AffymaxAsia-PacificLicensingNephrology and HepatologypeginesatidePharmaceuticalTakeda Pharmaceuticals

FDA committee backs Affymax CKD drug


The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

US FDA sets PDUFA action dates for Bydureon and peginesatide


US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Affymax gets $10 million milestone from Takeda on peginesatide NDA acceptance


California, USA-based Affymax (Nasdaq: AFFY) says it has received a $10 million development milestone…

AffymaxFinancialHematideOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top